NKGen Biotech, Inc., a clinical-stage biotechnology company, develops cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells. Its lead products include SNK01, an autologous NK cell therapy candidate for the treatment of neurodegenerative diseases, and SNK02, an allogeneic NK cell therapy for refractory solid tumors. The company has a license agreement with NKMAX for its NK cell program. The company has a strategic partnership with HekaBio K.K. for the development of the company's autologous NK cell therapy, troculeucel, in Japan. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Metrics to compare | NKGN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNKGNPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.2x | −3.4x | −0.5x | |
PEG Ratio | 0.00 | 0.01 | 0.00 | |
Price/Book | −0.2x | 2.6x | 2.6x | |
Price / LTM Sales | - | 9.3x | 3.3x | |
Upside (Analyst Target) | - | 197.5% | 45.4% | |
Fair Value Upside | Unlock | 15.1% | 7.7% | Unlock |